#Netherlands #Utrecht #Kaleido #Diabeloop #Dexcom G7

ViCentra's Revolutionary Insulin Therapy System

In a significant advancement for diabetes management, ViCentra has announced plans to launch its cutting-edge smartphone-based closed loop insulin therapy in early 2026. The system, which is designed to enhance the lives of individuals living with diabetes, blends the sleek and lightweight Kaleido insulin patch pump with Diabeloop's innovative DBLG2 algorithm. This launch comes shortly after the DBLG2 algorithm received the CE Mark approval, allowing it to function under the EU Medical Device Regulation.

The Kaleido patch pump itself is an engineering marvel—small, discreet, and crafted for comfort. This device aims to provide a seamless experience for diabetes patients, eliminating the need for cumbersome equipment. It is coupled with the DBLG2 algorithm, which promotes automated insulin delivery via a user-friendly app directly accessible on supported smartphones. This integration marks a pivotal moment in diabetes technology, empowering users to manage their condition with enhanced sophistication and ease.

ViCentra's Chief Executive Officer, Tom Arnold, emphasized that the Kaleido system is designed with the user in mind. He stated, "Kaleido is built for people, not just glucose levels," highlighting the company’s commitment to prioritizing user-centric design and functionality. The objective is clear: to elevate diabetes management into a more humanized, flexible experience.

Additionally, the introduction of the Dexcom G7 continuous glucose monitoring (CGM) system amplifies the capabilities of the Kaleido system. Notably, the Dexcom G7 is compact—60% smaller than its predecessor—and combines a sensor and transmitter in one streamlined device. This means that users can expect improved accuracy and easier monitoring without the burden of frequent fingerstick tests.

Launch Plans and User Engagement

ViCentra and Diabeloop are gearing up for a phased introduction of the new system, with early engagements scheduled in Germany and the Netherlands. Through a careful pre-launch phase, the companies aim to gather real-world feedback from users and healthcare providers alike. This information will be invaluable as they prepare for the full-scale commercial launch set for early 2026.

The collaboration between ViCentra and Diabeloop marks a significant milestone in their relationship, with mutual congratulations shared over the successful CE Mark approval for the DBLG2 algorithm. As healthcare technology evolves, partnerships like this one emphasize the importance of collaborative innovation.

Features for Today’s Diabetics

The forthcoming system will offer several key features that stand out:

• - Smartphone Integration: Users don’t require a separate controller to manage insulin delivery, allowing for seamless interaction with their diabetes management.
• - Advanced CGM Technology: The Dexcom G7 features integrated capabilities that enhance accuracy and user experience, contributing to more effective diabetes management strategies.
• - Design and Usability: The Kaleido patch pump is not just functional—it is also aesthetically pleasing and designed to fit the lifestyles of those who use it.

About ViCentra

Founded with a vision to transform diabetes care, ViCentra is dedicated to innovating solutions that resonate with the daily lives of patients. The company's headquarters is in Utrecht, the Netherlands, and it continues to reach new markets across Europe while eyeing expansion into the U.S. healthcare landscape.

As ViCentra approaches this exciting launch, anticipation grows about how its new technology will change the conversation around diabetes management. By placing an emphasis on user-friendly technology and thoughtful design, the company is setting a new standard for both function and form in the medical device industry.

With these advancements in mobile technology, ViCentra is not only boosting the confidence of diabetes patients but is also paving the way for future developments that prioritize quality of life alongside essential medical needs.